Elly | $8,000,000 | (Feb 26, 2026)
Profitmind | $9,000,000 | (Feb 26, 2026)
Abram Scientific | $11,750,000 | (Feb 26, 2026)
Sudo Biosciences
United States
- Menlo Park, California
- 21/12/2023
- Series B
- $116,000,000
Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.
- Industry Biotechnology Research
- Website https://www.sudobio.com/
- LinkedIn https://www.linkedin.com/company/sudo-biosciences/
Related People
Scott ByrdFounder
United States -
Zionsville, Indiana
Professional experience includes cross-functional roles across multiple therapeutic areas in the pharmaceutical industry: marketing, corporate strategy, commercial strategy, clinical development strategy, sales, hospital product sales and marketing, corporate finance, engineering, and manufacturing.
Specialties: Pharmaceutical marketing, pharmaceutical sales, hospital marketing, hospital sales, marketing strategy, coporate strategy, finance, pharmaceutical pricing reimbursement and access, pharmaceutical launch experience, cardiovascular, critical care, infectious disease.
Allica Bank | $155,000,000 | (Feb 26, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)
Quill Meetings | $6,500,000 | (Feb 26, 2026)
Avisi Technologies | $10,700,000 | (Feb 26, 2026)
TBD | $3,000,000 | (Feb 26, 2026)
NationGraph | $18,000,000 | (Feb 26, 2026)
Cicada | $13,500,000 | (Feb 26, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)